A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs BION 1301 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Aduro BioTech
- 18 Dec 2017 According to an Aduro Biotech media release, the first patient has been dosed at the Virginia Cancer Specialists in Fairfax, Virginia.
- 13 Nov 2017 Status changed from planning to recruiting.
- 31 Oct 2017 According to an Aduro Biotech media release, the FDA has cleared the IND for this trial.